Bristol Myers Squibb vs. Novo Nordisk: Stable Scale vs. GLP-1 Volatility

Bristol-Myers Squibb and Novo Nordisk, two leading pharmaceutical companies, showcase contrasting revenue models and growth strategies. Bristol-Myers Squibb primarily generates revenue from complex prescription drugs for cancer, cardiovascular issues, and immunological diseases. Recently, the company has invested billions of dollars to build a Texas manufacturing campus and secured accelerated FDA approval for a multiple myeloma treatment.

In contrast, Novo Nordisk focuses on manufacturing and distributing medical treatments for diabetes and obesity, experiencing a recent FDA review period delay for a hemophilia treatment candidate. Both companies reported revenue over the past eight quarters, with Novo Nordisk experiencing a 32% jump in Q1 2026 due to the launch of its weight-loss pill Wegovy in the U.S. However, Novo Nordisk's revenue fell short in Q2 2026, dropping 6% following earnings, due to seasonality, pricing pressures, and slower new product sales.

Despite the setback, Novo Nordisk's Ozempic and Wegovy account for 70% of its total sales, while Bristol-Myers Squibb's revenue growth comes from its growth portfolio, which now represents 58% of its revenue. Investors should consider the long-term potential of these companies, focusing on their diverse product lines and growth strategies rather than being swayed by quarterly results.